New data suggests that the US is at risk of losing its leadership in biomedical innovation, with china rapidly closing the gap. The migration of clinical trials and manufacturing abroad may be contributing to this trend. However, the situation is unclear, as some reports appear to be unrelated to the issue of US biomedical innovation leadership, discussing instead topics such as regulatory fluctuations, ai innovation, and stem rankings.